Literature DB >> 10319452

Contribution of mass spectrometry to contemporary immunology.

A de Jong1.   

Abstract

Mass spectrometry has become an increasingly important tool in the characterization of histocompatibility complex molecule (MHC) bound antigen peptides. It is one of the few technologies capable of identifying minute amounts of peptides in complex (5,000-10,000 constituents) MHC elution mixtures. Currently, the combination of tandem mass spectrometry with electrospray ionization (ESI) and microcapillary liquid chromatography (microLC) has proven to be the more versatile and effective technology. Post-source decay (PSD) and on-slide digestion combined with matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) may be valuable as well in certain circumstances. Recent refinements in the technology, such as the development of the quadrupole ion trap (QIT), Fourier transform ion cyclotron resonance (FTICR), and orthogonal quadrupole-time-of-flight (qToF) mass spectrometers equipped with nanoscale electrospray ionization sources and combined with microscale LC or capillary zone electrophoresis (CZE) yield attomole-range sensitivity in peptide sequencing, a level approaching the immuno-relevant level to a significant extent. In this review, past and ongoing developments in mass spectrometry and analytical separation techniques and their application to contemporary immunology are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10319452     DOI: 10.1002/(SICI)1098-2787(1998)17:5<311::AID-MAS1>3.0.CO;2-E

Source DB:  PubMed          Journal:  Mass Spectrom Rev        ISSN: 0277-7037            Impact factor:   10.946


  9 in total

1.  Obtaining more accurate Fourier transform ion cyclotron resonance mass measurements without internal standards using multiply charged ions.

Authors:  J E Bruce; G A Anderson; M D Brands; L Pasa-Tolic; R D Smith
Journal:  J Am Soc Mass Spectrom       Date:  2000-05       Impact factor: 3.109

2.  Large-scale analysis of HLA peptides presented by HLA-Cw4.

Authors:  Samuel Buchsbaum; Eilon Barnea; Lior Dassau; Ilan Beer; Elena Milner; Arie Admon
Journal:  Immunogenetics       Date:  2003-05-16       Impact factor: 2.846

Review 3.  Development of a Chlamydia trachomatis T cell Vaccine.

Authors:  Karuna P Karunakaran; Hong Yu; Leonard J Foster; Robert C Brunham
Journal:  Hum Vaccin       Date:  2010-08-01

Review 4.  MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.

Authors:  Joseph D Comber; Ramila Philip
Journal:  Ther Adv Vaccines       Date:  2014-05

5.  Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.

Authors:  Karuna P Karunakaran; Hong Yu; Xiaozhou Jiang; Queenie Chan; Kyung-Mee Moon; Leonard J Foster; Robert C Brunham
Journal:  Vaccine       Date:  2015-03-01       Impact factor: 3.641

6.  Gangliosides from human granulocytes: a nano-ESI QTOF mass spectrometry fucosylation study of low abundance species in complex mixtures.

Authors:  W Metelmann; J Peter-Katalinić; J Müthing
Journal:  J Am Soc Mass Spectrom       Date:  2001-08       Impact factor: 3.109

7.  Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells.

Authors:  Hong Yu; Karuna P Karunakaran; Isabelle Kelly; Caixia Shen; Xiaozhou Jiang; Leonard J Foster; Robert C Brunham
Journal:  J Immunol       Date:  2011-02-04       Impact factor: 5.422

8.  Role of T-cell epitope-based vaccine in prophylactic and therapeutic applications.

Authors:  James S Testa; Ramila Philip
Journal:  Future Virol       Date:  2012-11-01       Impact factor: 1.831

Review 9.  Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

Authors:  Pablo A González; Leandro J Carreño; Pablo F Céspedes; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Clin Dev Immunol       Date:  2013-03-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.